Risk Factor Control and #Cardiovascular Event Risk in People With Type 2 #Diabetes in Primary and Secondary Prevention Settings

To examine the association between the degree of risk factor control and cardiovascular disease (CVD) risk in type 2 diabetes and to assess if the presence of cardio-renal disease modifies these relationships. A retrospective cohort study using data from English practices from CPRD GOLD (Clinical Practice Research Datalink) and the SCI-Diabetes dataset (Scottish Care Information-Diabetes), with linkage to hospital and mortality data. We identified 101 749 … Continue reading Risk Factor Control and #Cardiovascular Event Risk in People With Type 2 #Diabetes in Primary and Secondary Prevention Settings

The #Kidney Disease: Improving Global Outcomes (KDIGO) 2020 Clinical Practice Guideline for #Diabetes Management in Chronic Kidney Disease (CKD)

Here attached you may find the takeaways of the guidelines for patients and for clinicians. takeaways for patients: https://kdigo.org/wp-content/uploads/2018/03/Top-10-Takeaways-Patients.pdf takeaways for clinicians: https://kdigo.org/wp-content/uploads/2018/03/Top-10-Takeaways-Clinicians.pdf Continue reading The #Kidney Disease: Improving Global Outcomes (KDIGO) 2020 Clinical Practice Guideline for #Diabetes Management in Chronic Kidney Disease (CKD)

Low High‐Sensitivity C‐ #Reactive Protein Level in Korean Patients With Chronic #Kidney Disease and Its Predictive Significance for Cardiovascular Events, Mortality, and Adverse Kidney Outcomes: Results From KNOW‐CKD

Inflammation levels are lower in East Asians than in Western people. We studied the association between high‐sensitivity hs‐CRP (C‐reactive protein) and adverse outcomes in Korean patients with chronic kidney disease. Methods and Results We included 2018 participants from the KNOW‐CKD (Korean Cohort Study for Outcome in Patients With Chronic Kidney Disease) between April 2011 and February 2016. The primary outcome was a composite of extended … Continue reading Low High‐Sensitivity C‐ #Reactive Protein Level in Korean Patients With Chronic #Kidney Disease and Its Predictive Significance for Cardiovascular Events, Mortality, and Adverse Kidney Outcomes: Results From KNOW‐CKD

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes

Finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist, reduced albuminuria in short-term trials involving patients with chronic kidney disease (CKD) and type 2 diabetes. However, its long-term effects on kidney and cardiovascular outcomes are unknown. ..During a median follow-up of 2.6 years, a primary outcome event occurred in 504 of 2833 patients (17.8%) in the finerenone group and 600 of 2841 patients (21.1%) in the placebo … Continue reading Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes

#Hypoalbuminemia is associated with increased risk of acute #kidney injury in hospitalized patients: A meta-analysis

Highlights • Each 1.0 g/dL of serum albumin decrement was associated with increased odds of AKI (OR 1.685; 95% CI, 1.302–2.179). • The risk factors for AKI in hypoalbuminemic patients include 1) age ≥ 70 years and 2) baseline serum albumin level > 3.2 g/dL. • The association between hypoalbuminemia and overall mortality from AKI remained inconclusive as there was potential publication bias. https://bit.ly/2HeU31v Continue reading #Hypoalbuminemia is associated with increased risk of acute #kidney injury in hospitalized patients: A meta-analysis

#Dapagliflozin in Patients with Chronic #Kidney Disease

Patients with chronic kidney disease have a high risk of adverse kidney and cardiovascular outcomes. The effect of dapagliflozin in patients with chronic kidney disease, with or without type 2 diabetes, is not known.. ..The independent data monitoring committee recommended stopping the trial because of efficacy. Over a median of 2.4 years, a primary outcome event occurred in 197 of 2152 participants (9.2%) in the … Continue reading #Dapagliflozin in Patients with Chronic #Kidney Disease

Natural history of acute #kidney disease in patients with #cirrhosis

In 2012, KDIGO group proposed new definitions for Acute Kidney Injury (AKI), Acute Kidney Disease (AKD) and Chronic Kidney Disease (CKD). According to the definition adapted by the International Club of Ascites (ICA), AKI has been extensively investigated in patients with cirrhosis. On the contrary, there are currently no data on the epidemiology and clinical outcome of AKD in these patients. The aim of the … Continue reading Natural history of acute #kidney disease in patients with #cirrhosis

The change in #kidney function was associated with #carotid artery plaque in a community-based population: a cohort study

We performed the current study to evaluate the association between dynamic change in estimated glomerular filtration rate (eGFR) and the risk of carotid artery plaque (CAP) in a community-based population A total number of 37,093 Chinese adults (21,790 men and 15,303 women, aged 42.6±11.6 years) free of chronic kidney diseases were enrolled. The change in eGFR was calculated based on two measurements in 2013 and … Continue reading The change in #kidney function was associated with #carotid artery plaque in a community-based population: a cohort study

2020 Conversion of Urine Protein–Creatinine Ratio or Urine Dipstick Protein to Urine Albumin–Creatinine Ratio for Use in Chronic Kidney Disease Screening and Prognosis

Measuring albuminuria is the preferred method for defining and staging chronic kidney disease (CKD), but total urine protein or dipstick protein is often measured instead. This analysis presents equations for converting urine protein–creatinine ratio and dipstick protein to urine albumin–creatinine ratio, and finds that both may help in CKD screening, staging, and prognosis.. Equations to convert urine PCR and dipstick protein to ACR were developed … Continue reading 2020 Conversion of Urine Protein–Creatinine Ratio or Urine Dipstick Protein to Urine Albumin–Creatinine Ratio for Use in Chronic Kidney Disease Screening and Prognosis

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial

Sodium-glucose co-transporter-2 (SGLT2) inhibitors have shown beneficial effects on renal outcomes mainly in patients with established atherosclerotic cardiovascular disease. Here we report analyses of renal outcomes with the SGLT2 inhibitor dapagliflozin in the DECLARE–TIMI 58 cardiovascular outcomes trial, which included patients with type 2 diabetes both with and without established atherosclerotic cardiovascular disease and mostly with preserved renal function.. ..The trial took place between April … Continue reading Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial

Glycemic Status, Insulin Resistance, and the Risk of Nephrolithiasis: A Cohort Study

..During a median follow-up of 4.2 years, 6,904 participants developed nephrolithiasis. Associations between levels of glycemic status and incident nephrolithiasis were examined separately in men and women ( P for interaction = 0.003). Among men, multivariable-adjusted HRs for incident nephrolithiasis comparing glucose levels of 90-99, 100-125, and 126-<90 mg/dL were 1.10 (95% CI, 1.01-1.19), 1.11 (95% CI, 1.02-1.21), and 1.27 (95% CI, 1.10-1.46), respectively, while … Continue reading Glycemic Status, Insulin Resistance, and the Risk of Nephrolithiasis: A Cohort Study

Assessment of #dextrose 50 bolus versus dextrose 10 infusion in the management of #hyperkalemia in the ED

Hypoglycemia is a common adverse effect when intravenous (IV) insulin is administered for hyperkalemia. A prolonged infusion of dextrose 10% (D10) may mitigate hypoglycemia compared to dextrose 50% (D50) bolus. Our objective was to evaluate whether D10 infusion is a safe and effective alternative to D50 bolus for hypoglycemia prevention in hyperkalemic patients receiving IV insulin.. ..There was no difference in incidence of hypoglycemia between … Continue reading Assessment of #dextrose 50 bolus versus dextrose 10 infusion in the management of #hyperkalemia in the ED